RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Sihuan Pharma has started a China Phase II Trial of pirotinib, a novel EGFR treatment for cancer, in patients with non-small cell lung cancer (NSCLC). The company conducted the earlier Phase I trial in the US. Sihuan, which claims to be the largest cardio-cerebral vascular drug maker in China, developed the candidate through its own R&D efforts. Sihuan was the first China biopharma to privatize from an ex-China exchange and then re-list in China, raising $741 million in a 2010 Hong Kong IPO.
Source: China Biotoday